Nexus Magazine - Vol 22 #3, April-May 2015 by Nexus various

Author:Nexus various
Language: eng
Format: epub
Published: 2015-04-10T04:00:00+00:00

Success Stories with SLAGE and Triple G

Sister Ena's anecdotal record is the first of several that validate the importance of the SLAGE discovery and subsequent Triple G development.

In a letter written by Sister Damien, dated 25 January 2004, the following factual observations were made: Sister Ena commenced the Triple G extract by itself on 16 November 2002 until 22 January 2003 at a dosage of 5 mL daily. Within three weeks she had brightened up, and as the weeks passed she participated with enthusiasm in community prayers and fun discussions at the dinner table. Her memory improved vastly. From February 2003, at the suggestion of Sister Damien, she was given 5 mg folic acid plus a commercial vitamin B complex which I recommended. Sister Ena's condition steadily improved but sadly, as a result of a fall in July 2003, she became a nursing home resident and the regime was ceased. Sister Ena regressed from that point onwards.

Dr P., who liked alternative medicines and was suitably impressed with Sister Ena's results, recommended in December 2002 that an 80-year-old male patient diagnosed with moderate dementia undergo a trial of the Triple G extract together with vitamin B and folic acid. The patient took the Triple G formula at a dosage of 5 mL per day for approximately 11 months, and although his clinical picture did not improve he did not deteriorate further, according to Dr P.'s letter of 10 February 2004.

Two further volunteers "presented" themselves in 2010 and 2014.

The first was a 62-year-old man with short-term memory loss as a result of a stroke that he suffered in 1994 and subsequent craniotomy surgery that he underwent as part of his therapy.

In a letter that Mr B. wrote in December 2010, he claims that the Triple G regime overcame his short-term memory problems. However, he found that a dose of 5 mL was too much for him and he reduced it by half.

In July 2014, I was approached by the daughter of Mr T., aged 78, in an effort to help resolve his clinically diagnosed dementia. His medical condition was confirmed by the mini-mental state examination (MMSE) which he failed, and various brain scans which indicated atrophy of the brain. Mr T. had previously suffered a stroke.

Mr T.'s increasing lapses of memory had prompted medical intervention. One of these lapses had a tragic consequence: Mr T. had forgotten where he'd left his pet dog. A thorough search by relatives revealed that Mr T. had locked his pet dog in his car. This was during the hot summer of 2013, and the dog perished due to heat exhaustion.

Mr T.'s GP referred him to take part in a double-blind clinical trial conducted by a neurologist at a teaching hospital. The trial involved the medication Aricept® (donezepil), commenced at a dosage of 5 mg per day. Mr T commenced the treatment in November 2013 and voluntarily ceased it in late January 2014 due to its adverse gastrointestinal tract side effects. Mr T. experienced diarrhoea, which he

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.